Cargando…
Fatigue in idiopathic pulmonary fibrosis measured by the Fatigue Assessment Scale during antifibrotic treatment
Background: Fatigue is a common complaint in patients with idiopathic pulmonary fibrosis (IPF) and has been reported in a considerable percentage of patients. Fatigue is also a registered side effect of pirfenidone, one of two approved antifibrotic drugs. The Fatigue Assessment Scale (FAS) was devel...
Autores principales: | Kølner-Augustson, Line, Prior, Thomas Skovhus, Skivild, Vibeke, Aalestrup, Anette, Bendstrup, Elisabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717873/ https://www.ncbi.nlm.nih.gov/pubmed/33312458 http://dx.doi.org/10.1080/20018525.2020.1853658 |
Ejemplares similares
-
Risk factors for diagnostic delay in idiopathic pulmonary fibrosis
por: Hoyer, Nils, et al.
Publicado: (2019) -
Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis
por: Prior, Thomas Skovhus, et al.
Publicado: (2020) -
Validation of the King’s Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis
por: Prior, Thomas Skovhus, et al.
Publicado: (2019) -
ANTIFIBROTIC THERAPY IN IDIOPATHIC PULMONARY FIBROSIS
por: Scullion, T., et al.
Publicado: (2017) -
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)